Skip to main content
TTRX
NASDAQ Life Sciences

Turn Therapeutics Announces Broad Positive Updates: Clinical Progress, New Board Member, Pipeline Expansion, Commercial Revenue, and Extended Financial Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.604
Mkt Cap
$136.92M
52W Low
$2.57
52W High
$26.5
52W Position info
79% above low
Off High info
83% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

TTRX sits 79% above its 52-week low of $2.57 on light trading volume (0.1× avg).

Summary

Turn Therapeutics announced multiple positive developments including clinical trial progress, a key board appointment, pipeline expansion, anticipated commercial revenue, and an extended financial runway.


Key Events · Corporate Governance and Compliance · TTRX

  • Clinical Trial Progress

    The Phase 2 trial for GX-03 in moderate-severe atopic dermatitis remains on track for both interim analysis and topline data in the first half of 2026.

  • Board Appointment

    Martin Dewhurst, a veteran with over 30 years of experience in life sciences, mergers and acquisitions, and corporate strategy from McKinsey & Company, has been appointed to the Board of Directors.

  • Vaccine Pipeline Expansion

    The company expanded its vaccine pipeline to include an intranasal Influenza candidate, with in-vivo and in-vitro studies expected to commence in the first quarter of 2026.

  • Commercial Partnership Revenue

    A strategic partnership with Medline is expected to generate near-term revenue in the advanced wound care market in 2026.


Analysis · TTRX · Life Sciences

Turn Therapeutics provided a comprehensive update highlighting significant progress across its clinical development, corporate governance, pipeline expansion, commercial strategy, and financial stability. The appointment of a seasoned M&A veteran to the board, the expansion into a new vaccine candidate, and the expectation of near-term revenue from a strategic partnership are all positive indicators. Crucially, the company has strengthened its balance sheet, extending its operational runway into late 2026, which de-risks its near-term financial position and supports continued execution of its strategic objectives.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TTRX was trading at $4.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $136.9M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TTRX - Latest Insights

TTRX
Nov 16, 2026, 4:23 PM EST
Filing Type: 424B3
Importance Score:
7
Price at Filing: $8.55
Real-time Price: $8.00 info
Change: -$0.5475 (-6%) info
Market Cap: $247.486M info
TTRX
Nov 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.79
Real-time Price: $8.00 info
Change: -$1.79 (-18%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 8:05 AM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 8:00 AM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 7:02 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info